Ban on Nimesulide Formulations
Context:
The Union Health Ministry has issued a ban on the manufacture, sale, and distribution of oral formulations of Nimesulide exceeding 100 mg in immediate-release dosage forms.
This decision follows concerns regarding the drug's safety profile.
About Nimesulide:
It is a Non-Steroidal Anti-Inflammatory Drug (NSAID).
It is prescribed for acute pain, symptomatic relief in osteoarthritis, and primary dysmenorrhea (painful menstruation).
It provides pain-relieving, anti-inflammatory, and fever-reducing effects.
It is primarily intended as a second-line treatment for short-term use.
Reason for the Ban:
The government acted on concerns regarding potential liver toxicity associated with high doses.
The Health Ministry stated that the risk to human beings outweighs the benefits for this specific dosage, especially since safer alternatives are available.
Key Provisions of the Ban:
The ban was imposed under Section 26A of the Drugs and Cosmetics Act, 1940, following consultation with the Drugs Technical Advisory Board.
Oral immediate-release formulations above 100 mg are banned
What are permitted?
Oral formulations of 100 mg or below
Sustained/Extended-release formulations (even if above 100 mg).
Non-oral formulations (such as topical gels, creams, and suppositories)